A pilot study to assess smokeless tobacco use reduction with varenicline

Jon Owen Ebbert, Ivana T Croghan, Frederick North, Darrell R. Schroeder

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Long-term smokeless tobacco (ST) use is known to increase the risk for oropharyngeal cancer, heart attack, and stroke. Extant literature on cigarette smokers suggests that smoking reduction increases smoking abstinence among smokers not interested in quitting. Similarly, a reduction strategy may reduce ST exposure and increase ST abstinence rates among ST users not interested in quitting. Methods: We conducted a pilot study to obtain preliminary data on the use of 12 weeks of varenicline as a tobacco reduction strategy among ST users not interested in quitting. Results: We enrolled 20 male ST users with a mean age of 42.8 ± 11.7 years who used an average of 3.9 ± 1.7 cans/pouches per week for 18.6 ± 8.6 years. At end of treatment (12 weeks), 60% (12/20) of subjects reduced their ST use by ≥50% and 15% (3/20) were biochemically confirmed abstinent from tobacco. At end of study (6 months), 50% (10/20) reduced by ≥50% of baseline use and 10% (2/20) were biochemically confirmed abstinent from tobacco. Varenicline reduced ST satisfaction, reward, and craving. Among subjects able to reduce ST, all subjects reported that reduction increased motivation and confidence in being able to maintain reduction and quit. The most common side effects were sleep disturbance (25%) and nausea (15%). Discussion: Varenicline may be effective in reducing ST use and achieving ST abstinence among ST users with no plans to quit but who are interested in reducing their ST use.

Original languageEnglish (US)
Pages (from-to)1037-1040
Number of pages4
JournalNicotine and Tobacco Research
Volume12
Issue number10
DOIs
StatePublished - Aug 19 2010

Fingerprint

Smokeless Tobacco
Tobacco Use
Tobacco
Varenicline
Smoking
Oropharyngeal Neoplasms
Reward
Tobacco Products
Nausea
Motivation

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

A pilot study to assess smokeless tobacco use reduction with varenicline. / Ebbert, Jon Owen; Croghan, Ivana T; North, Frederick; Schroeder, Darrell R.

In: Nicotine and Tobacco Research, Vol. 12, No. 10, 19.08.2010, p. 1037-1040.

Research output: Contribution to journalArticle

Ebbert, Jon Owen ; Croghan, Ivana T ; North, Frederick ; Schroeder, Darrell R. / A pilot study to assess smokeless tobacco use reduction with varenicline. In: Nicotine and Tobacco Research. 2010 ; Vol. 12, No. 10. pp. 1037-1040.
@article{1dbbf104df374a0f8e8c0e10cb34f66f,
title = "A pilot study to assess smokeless tobacco use reduction with varenicline",
abstract = "Introduction: Long-term smokeless tobacco (ST) use is known to increase the risk for oropharyngeal cancer, heart attack, and stroke. Extant literature on cigarette smokers suggests that smoking reduction increases smoking abstinence among smokers not interested in quitting. Similarly, a reduction strategy may reduce ST exposure and increase ST abstinence rates among ST users not interested in quitting. Methods: We conducted a pilot study to obtain preliminary data on the use of 12 weeks of varenicline as a tobacco reduction strategy among ST users not interested in quitting. Results: We enrolled 20 male ST users with a mean age of 42.8 ± 11.7 years who used an average of 3.9 ± 1.7 cans/pouches per week for 18.6 ± 8.6 years. At end of treatment (12 weeks), 60{\%} (12/20) of subjects reduced their ST use by ≥50{\%} and 15{\%} (3/20) were biochemically confirmed abstinent from tobacco. At end of study (6 months), 50{\%} (10/20) reduced by ≥50{\%} of baseline use and 10{\%} (2/20) were biochemically confirmed abstinent from tobacco. Varenicline reduced ST satisfaction, reward, and craving. Among subjects able to reduce ST, all subjects reported that reduction increased motivation and confidence in being able to maintain reduction and quit. The most common side effects were sleep disturbance (25{\%}) and nausea (15{\%}). Discussion: Varenicline may be effective in reducing ST use and achieving ST abstinence among ST users with no plans to quit but who are interested in reducing their ST use.",
author = "Ebbert, {Jon Owen} and Croghan, {Ivana T} and Frederick North and Schroeder, {Darrell R.}",
year = "2010",
month = "8",
day = "19",
doi = "10.1093/ntr/ntq134",
language = "English (US)",
volume = "12",
pages = "1037--1040",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - A pilot study to assess smokeless tobacco use reduction with varenicline

AU - Ebbert, Jon Owen

AU - Croghan, Ivana T

AU - North, Frederick

AU - Schroeder, Darrell R.

PY - 2010/8/19

Y1 - 2010/8/19

N2 - Introduction: Long-term smokeless tobacco (ST) use is known to increase the risk for oropharyngeal cancer, heart attack, and stroke. Extant literature on cigarette smokers suggests that smoking reduction increases smoking abstinence among smokers not interested in quitting. Similarly, a reduction strategy may reduce ST exposure and increase ST abstinence rates among ST users not interested in quitting. Methods: We conducted a pilot study to obtain preliminary data on the use of 12 weeks of varenicline as a tobacco reduction strategy among ST users not interested in quitting. Results: We enrolled 20 male ST users with a mean age of 42.8 ± 11.7 years who used an average of 3.9 ± 1.7 cans/pouches per week for 18.6 ± 8.6 years. At end of treatment (12 weeks), 60% (12/20) of subjects reduced their ST use by ≥50% and 15% (3/20) were biochemically confirmed abstinent from tobacco. At end of study (6 months), 50% (10/20) reduced by ≥50% of baseline use and 10% (2/20) were biochemically confirmed abstinent from tobacco. Varenicline reduced ST satisfaction, reward, and craving. Among subjects able to reduce ST, all subjects reported that reduction increased motivation and confidence in being able to maintain reduction and quit. The most common side effects were sleep disturbance (25%) and nausea (15%). Discussion: Varenicline may be effective in reducing ST use and achieving ST abstinence among ST users with no plans to quit but who are interested in reducing their ST use.

AB - Introduction: Long-term smokeless tobacco (ST) use is known to increase the risk for oropharyngeal cancer, heart attack, and stroke. Extant literature on cigarette smokers suggests that smoking reduction increases smoking abstinence among smokers not interested in quitting. Similarly, a reduction strategy may reduce ST exposure and increase ST abstinence rates among ST users not interested in quitting. Methods: We conducted a pilot study to obtain preliminary data on the use of 12 weeks of varenicline as a tobacco reduction strategy among ST users not interested in quitting. Results: We enrolled 20 male ST users with a mean age of 42.8 ± 11.7 years who used an average of 3.9 ± 1.7 cans/pouches per week for 18.6 ± 8.6 years. At end of treatment (12 weeks), 60% (12/20) of subjects reduced their ST use by ≥50% and 15% (3/20) were biochemically confirmed abstinent from tobacco. At end of study (6 months), 50% (10/20) reduced by ≥50% of baseline use and 10% (2/20) were biochemically confirmed abstinent from tobacco. Varenicline reduced ST satisfaction, reward, and craving. Among subjects able to reduce ST, all subjects reported that reduction increased motivation and confidence in being able to maintain reduction and quit. The most common side effects were sleep disturbance (25%) and nausea (15%). Discussion: Varenicline may be effective in reducing ST use and achieving ST abstinence among ST users with no plans to quit but who are interested in reducing their ST use.

UR - http://www.scopus.com/inward/record.url?scp=77957747183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957747183&partnerID=8YFLogxK

U2 - 10.1093/ntr/ntq134

DO - 10.1093/ntr/ntq134

M3 - Article

VL - 12

SP - 1037

EP - 1040

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 10

ER -